Suppression of p16 alleviates the senescence-associated secretory phenotype
Raquel Buj(Penn State Milton S. Hershey Medical Center), Katherine M. Aird(The Wistar Institute)
Cited by 10
Related Papers
EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer
|The EMBO Journal|2015|72
<i>De Novo</i> Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
|Cancer Research Communications|2024|9
αKG-mediated carnitine synthesis promotes homologous recombination via histone acetylation
|bioRxiv (Cold Spring Harbor Laboratory)|2024|7
ATR promotes mTORC1 activity via <i>de novo</i> cholesterol synthesis
|bioRxiv (Cold Spring Harbor Laboratory)|2023|4
De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1